Drug Discount Agreements for Formoterol, Glycopyrroniumbromid, and Budesonid
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol, Glycopyrroniumbromid und Budesonid, ATC R03AL11
Opportunity Score
Why this score?
Opportunity
35 / 100
Complexity
20 / 100
Risk factors
No estimated value or budget is provided. The actual volume depends entirely on prescription behavior and the discount...
The open-house agreement can be automatically superseded if a standard procurement discount agreement for the same acti...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Non-exclusive drug discount agreements for Formoterol, Glycopyrroniumbromid, and Budesonid (ATC R03AL11) under §130a Abs. 8 SGB V.
- All agreements are identical and non-negotiable.
Show full summary
This is an open-house model (not a classic procurement) by AOK Bayern for non-exclusive drug discount agreements on Formoterol, Glycopyrroniumbromid, and Budesonid (ATC R03AL11). Any eligible pharmaceutical company can enter into identical, non-negotiable discount agreements. The contract runs from 01.07.2025 to 30.06.2027, with possible earlier termination if other discount agreements come into effect. No estimated value is provided. Only eligibility criterion is a signed declaration of reliability. Submission is possible at any time until 05.05.2027. Documents must be submitted either in paper (two copies) or electronically with a qualified electronic signature.
Risks
No estimated value or budget is provided. The actual volume depends entirely on prescription behavior and the discount...
The open-house agreement can be automatically superseded if a standard procurement discount agreement for the same acti...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Only pharmaceutical companies can participate.
Eligibility
- Eligibility demonstrated by a signed declaration of reliability.
Administrative
- Signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Drug Discount Agreements for Formoterol, Glycopyrroniumbromid, and Budesonid
Open-house model for non-exclusive drug discount agreements on active ingredient combination Formoterol, Glycopyrroniumbromid, and Budesonid (ATC R03AL11). All eligible pharmaceutical companies can join on identical terms. No selection, no award criteria. Performance in Bavaria, Germany.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Formoterol, Glycopyrroniumbromid und Budesonid, ATC R03AL11
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 316968-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
35 / 100
Complexity
20 / 100
Risk factors
No estimated value or budget is provided. The actual volume depends entirely on prescription behavior and the discount...
The open-house agreement can be automatically superseded if a standard procurement discount agreement for the same acti...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications